DBV Technologies
Develops epicutaneous immunotherapy (EPIT) patch technology for food allergies.
DBV | PA
Overview
Corporate Details
- ISIN(s):
- FR0010417345 (+3 more)
- LEI:
- 969500PVBQFWQKVDMD80
- Country:
- France
- Address:
- 107 AVENUE DE LA REPUBLIQUE, 92320 CHATILLON
- Sector:
- Manufacturing
Description
DBV Technologies is a clinical-stage biopharmaceutical company developing treatments for food allergies and other immunological diseases. The company's core technology is Viaskin®, a proprietary investigational platform based on epicutaneous immunotherapy (EPIT). This non-invasive patch technology is designed to re-educate the immune system by delivering minimal amounts of antigens through intact skin. DBV's lead product candidate, Viaskin Peanut (DBV712), is in late-stage clinical development for the treatment of peanut allergies in pediatric patients. The development pipeline also includes Viaskin Milk (DBV135) for milk allergies, with the platform holding potential for applications beyond food allergies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-04-11 22:11 |
Document d'enregistrement universel 2024
|
French | 20.6 MB | ||
| 2025-04-04 11:17 |
Franchissement de seuils
|
French | 207.3 KB | ||
| 2025-04-03 16:59 |
Franchissement de seuils
|
French | 207.0 KB | ||
| 2025-03-28 03:30 |
DBV Technologies Annonce un Financement pouvant atteindre 306,9 millions de dol…
|
French | 416.3 KB | ||
| 2025-03-28 03:30 |
DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) t…
|
English | 385.1 KB | ||
| 2025-03-24 07:30 |
DBV Technologies conclut un accord avec la FDA sur les données d'innocuité requ…
|
French | 342.8 KB | ||
| 2025-03-24 07:30 |
DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required fo…
|
English | 325.3 KB | ||
| 2025-02-25 22:01 |
DBV Technologies participera au prochain congrès conjoint AAAAI/WAO
|
French | 237.6 KB | ||
| 2025-02-25 22:01 |
DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress
|
English | 244.4 KB | ||
| 2025-01-13 22:05 |
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
|
English | 197.4 KB | ||
| 2025-01-13 22:05 |
Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF
|
French | 195.2 KB | ||
| 2025-01-08 22:05 |
DBV Technologies présente les résultats positifs à 3 ans de l'étude de prolonga…
|
French | 288.0 KB | ||
| 2025-01-08 22:05 |
DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-La…
|
English | 287.5 KB | ||
| 2024-12-11 22:05 |
DBV confirme l’alignement avec la FDA (US) sur la procédure d'approbation accél…
|
French | 375.2 KB | ||
| 2024-12-11 22:05 |
DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Vi…
|
English | 193.2 KB |
Automate Your Workflow. Get a real-time feed of all DBV Technologies filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for DBV Technologies
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for DBV Technologies via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-06-09 | N/A | Other | Other | 2,483,161 | 7,449,483.00 EUR |
Peer Companies
